Extended spectrum β-lactamases, carbapenemases and mobile genetic elements responsible for antibiotics resistance in Gram-negative bacteria
- 6 June 2012
- journal article
- review article
- Published by Taylor & Francis in Critical Reviews in Microbiology
- Vol. 39 (2) , 113-122
Abstract
Infectious diseases due to Gram-negative bacteria are a leading cause of morbidity and mortality worldwide. Antimicrobial agents represent one major therapeutic tools implicated to treat these infections. The misuse of antimicrobial agents has resulted in the emergence of resistant strains of Gram-negatives in particular Enterobacteriaceae and non-fermenters; they have an effect not only on a human but on the public health when bacteria use the resistance mechanisms to spread in the hospital environment and to the community outside the hospitals by means of mobile genetic elements. Gram-negative bacteria have become increasingly resistant to antimicrobial agents. They have developed several mechanisms by which they can withstand to antimicrobials, these mechanisms include the production of Extended-spectrum β-lactamases (ESBLs) and carbapenemases, furthermore, Gram-negative bacteria are now capable of spreading such resistance between members of the family Enterobacteriaceae and non-fermenters using mobile genetic elements as vehicles for such resistance mechanisms rendering antibiotics useless. Therefore, addressing the issue of mechanisms of antimicrobial resistance is considered one of most urgent priorities. This review will help to illustrate different resistance mechanisms; ESBLs, carbapenemases encoded by genes carried by mobile genetic elements, which are used by Gram-negative bacteria to escape antimicrobial effect.Keywords
This publication has 88 references indexed in Scilit:
- Genetic Context and Biochemical Characterization of the IMP-18 Metallo-β-Lactamase Identified in a Pseudomonas aeruginosa Isolate from the United StatesAntimicrobial Agents and Chemotherapy, 2011
- Alarming β-lactamase-mediated resistance in multidrug-resistant EnterobacteriaceaeCurrent Opinion in Microbiology, 2010
- The Use of Carbapenems in the Treatment of Serious InfectionsJournal of Intensive Care Medicine, 2009
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- High Rate of Mobilization for bla CTX-M sEmerging Infectious Diseases, 2008
- Carbapenems in PediatricsTherapeutic Drug Monitoring, 2003
- Intracellular steps of bacterial cell wall peptidoglycan biosynthesis: enzymology, antibiotics, and antibiotic resistanceNatural Product Reports, 1992
- A new plasmidic cefotaximase in a clinical isolate of Escherichia coliInfection, 1990
- Carbapenems, a new class of beta-lactam antibioticsThe American Journal of Medicine, 1985
- The structure of β-lactamasesPhilosophical Transactions of the Royal Society of London. B, Biological Sciences, 1980